Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury

Gene Therapy

Volumn 13, Issue 4, 2006, Pages 296-303

  Araki, K ^a   Shiotani, A ^a   Watabe, K ^b   Saito, K ^a   Moro, K ^a   Ogawa, K ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Adenovirus; Cranial nerve injury; GDNF; Nucleus ambiguus; Recurrent laryngeal nerve; Vocal fold palsy

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA;

AMBIGUUS NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL LABELING; CONTROLLED STUDY; CRUSH TRAUMA; DRUG MECHANISM; GENE EXPRESSION; GENE TRANSFER; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECURRENT LARYNGEAL NERVE PALSY; REMYELINIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VOCAL CORD;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; ELECTROPHYSIOLOGY; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRALESIONAL; MOTOR NEURONS; NEURAL CONDUCTION; RATS; RATS, SPRAGUE-DAWLEY; RECURRENT LARYNGEAL NERVE; TRANSDUCTION, GENETIC; VOCAL CORD PARALYSIS;

ADENOVIRIDAE; ANIMALIA;

EID: 32444438913     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302665     Document Type: Article

References (48)

1. Isshiki N. Progress in laryngeal framework surgery. Acta Otolaryngol 2000; 120: 120-127.
2. Eisele DW. Complications of thyroid surgery. In: Eisele DW (ed) Complications in Head Neck Surgery. Mosby-Year Book: St Louis, 2000, pp 423-437.
3. Netterville JL, Aly A, Ossoff RH. Evaluation and treatment of complications of thyroid and parathyroid surgery. Otolaryngol Clin North Am 1990; 23: 529-552.
4. Goding GS. Nerve-muscle pedicle reinnervation of the paralyzed vocal cord. Otolaryngol Clin North Am 1991; 24: 1239-1252.
5. Horn KL, Crumley RL. The physiology of nerve injury and repair. Otolaryngo Clin North Am 1984; 17: 321-333.
6. Jacobs IN, Sanders I, Wu BL, Biller HF. Reinnervation of the canine posterior cricoarytenoid muscle with sympathetic preganglionic neurons. Ann Otol Rhinol Laryngol 1990; 99: 167-174.
7. Crumley RL. Mechanisms of synkinesis. Laryngoscope 1979; 89: 1847-1854.
8. Flint PW, Downs DH, Coltrera MD. Laryngeal synkinesis following reinnervation in the rat: Neuroanatomic and physiologic study using retrograde fluorescent tracers and electromyography. Ann Otol Rhinol Laryngol 1991; 100: 797-806.
9. Singleton JR, Dixit VM, Feldman EL. Type I insulin-like growth factor receptor activation regulates apoptotic proteins. J Biol Chem 1996; 271: 31791-31794.
10. Kim B, Leventhal PS, Saltiel AR, Feldman EL. Insulin-like growth factor-I-mediated neurite outgrowth in vitro requires MAP kinase activation. J Biol Chem 1997; 272: 21268-21273.
11. Russell JW, Windebank AJ, Schenone A, Feldman EL. Insulin like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal. J Neurobiol 1998; 36: 455-467.
12. Baumgartner BJ, Shine HD. Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population. J Neurosci 1997; 17: 6504-6511.
13. Ribotta MG, Revah F, Pradier L, Loquet I, Mallet J, Privat A. Prevention of motor neuron death by adenovirus-mediated neurotrophic factors. J Neurosci Res 1997; 48: 281-285.
14. Lewin GR. Neurotrophic factors and pain. Semin Neurosci 1995; 7: 227-232.
15. Dittrich FH, Thoenen H, Sendtner M. Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann Neurol 1994; 35: 151-163.
16. Houenou LJ, Oppenheim RW, Li L, Lo AC, Prevette D. Regulation of spinal motoneuron survival by GDNF during development and following injury. Cell Tissue Res 1996; 286: 219-223.
17. Lapchak PA, Jiao S, Miller PJ, Williams LR, Cummins V, Inouye G et al. Pharmacological characterization of GDNF as a therapeutic molecule for treating neurodegenerative diseases. Cell Tissue Res 1996; 286: 179-189.
18. Lindsay RM. Neuron saving schemes. Nature 1995; 373: 289-290.
19. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M et al. GDNF: A potent survival factor for motoneurons present in peripheral. Science 1994; 266: 1062-1064.
20. Li L, Wu W, Lin LF, Lei M, Oppenheim RW, Houenou LJ. Rescue of adult mouse motoneurons from injury-induced cell death by glial cell line-derived neurotrophic factor. Proc Natl Acad Sci USA 1995; 92: 9771-9775.
21. Yan Q, Matheson C, Lopez OT. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 1995; 373: 341-344.
22. Sakamoto T, Watabe K, Ohashi T, Kawazoe Y, Oyanagi K, Inoue K et al. Adenoviral vector-mediated GDNF gene transfer prevents death of adult facial motoneurons. Neuroreport 2000; 11: 1857-1860.
23. Nguyen QT, Parsadanian AS, Snider WD, Lichtman JW. Hyperinnervation of neuromuscular junctions caused by GDNF overexpression in muscle. Science 1998; 279: 1725-1729.
24. Hoke A, Cheng C, Zochodne DW. Expression of glial cell line-derived neurotrophic factor family of growth factors in peripheral nerve injury in rats. Neuroreport 2000; 11: 1651-1654.
25. Kang UJ. Genetic modification of cells with retrovirus vectors for grafting into the central nervous system. In: Kaplitt MG, Loewy AD (ed) Viral Vectors: Gene Therapy and Neuroscience Applications. Academic Press: San Diego, 1995, pp 211-237.
26. O'Malley Jr BW, Ledley FD. Somatic gene therapy in otolaryngology - head and neck surgery. Arch Otolaryngol Head Neck Surg 1993; 119: 1191-1197.
27. O'Malley Jr BW, Ledley FD. Somatic gene therapy: Methods for the present and future. Arch Otolaryngol Head Neck surg 1993; 119: 1100-1177.
28. Shiotani A, O'Malley Jr BW, Coleman ME, Alila HW, Flint PW. Reinnervation of motor endplates and increased muscle fiber size after human insulin-like growth factor I gene transfer into the paralyzed larynx. Hum Gene Ther 1998; 9: 2039-2047.
29. Shiotani A, O'Malley Jr BW, Coleman ME, Flint PW. Human insulin-like growth factor 1 gene transfer into paralyzed rat larynx: Single vs multiple injection. Arch Otolaryngol Head Neck Surg 1999; 125: 555-560.
30. Saito K, Shiotani A, Watabe K, Moro K, Fukuda H, Ogawa K. Adenoviral GDNF gene transfer prevents motoneuron loss in the nucleus ambiguus. Brain Res 2003; 962: 61-67.
31. Boulis NM, Bhatia V, Brindle TI, Holman HT, Krauss DJ, Blaivas M et al. Adenoviral nerve growth factor and beta-galactosidase transfer to spinal cord: A behavioral and histological analysis. J Neurosurg 1998; 90: 99-108.
32. Liu Y, Himes BT, Moul J, Huang W, Chow SY, Tessler A et al. Application of recombinant adenovirus for in vivo gene delivery to spinal cord. Brain Res 1997; 768: 19-29.
33. Boulis NM, Turner DE, Dice JA, Bhatia V, Feldman EL. Characterization of adenoviral gene expression in spinal cord after remote vector delivery. Neurosurgery 1999; 45: 131-138.
34. Ghadge GD, Roos RP, Kang UJ, Wollmann R, Fishman PS, Kalynych AM et al. CNS gene delivery by retrograde transport of recombinant replication - defective adenoviruses. Gene Therapy 1995; 2: 132-137.
35. Rubin AD, Hogikyan ND, Sullivan K, Boulis N, Feldman EL. Remote delivery of rAAV-GFP to the rat brainstem through the recurrent laryngeal nerve. Laryngoscope 2001; 111: 2041-2045.
36. Rubin A, Mobley B, Hogikyan N, Bell K, Sullivan K, Boulis N et al. Delivery of an adenoviral vector to the crushed recurrent laryngeal nerve. Laryngoscope 2003; 113: 985-989.
37. Varejao AS, Cabrita AM, Meek MF, Bulas-Cruz J, Melo-Pinto P, Raimondo S et al. Functional and morphological assessment of a standardized rat siatic nerve crush injury with a non-serrated clump. J Neurotrauma 2004; 21: 1652-1670.
38. Bridge P, Ball DJ, Mackinnon SE, Nakao Y, Brandt K, Hunter DA et al. Nerve crush injuries - A model for axonotmesis. Exp Neurol 1994; 127: 284-290.
39. Seddon HJ. Three types of nerve injury. Brain 1943; 66: 237.
40. Sunderland S. Classification of peripheral nerve injury producing loss of function. Brain 1951; 74: 491.
41. Zeng L, Worseg A, Albrecht G, Grisold W, Hopf R, Redl H et al. A noninvasive functional evaluation following peripheral nerve repair with electromyography in a rat model. Plast Reconstr Surg 1994; 94: 146-151.
42. Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L. Acute inflammatory response in spinal cord following impact injury. Exp Neurol 1998; 151: 77-88.
43. George JA. Gene therapy progress and prospects: Adenoviral vectors. Gene Therapy 2003; 10: 1135-1141.
44. Check E. Sanctions agreed over teenager's gene-therapy death. Nature 2005; 433: 674.
45. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
46. Watabe K, Ohashi T, Sakamoto T, Kawazoe Y, Takeshima T, Oyanagi K et al. Rescue of lesioned adult rat spinal motoneurons by adenoviral gene transfer of glial cell line-derived neurotrophic factor. J Neurosci Res 2000; 60: 511-519.
47. Kanegae Y, Takamori K, Sato Y, Lee G, Nakai M, Saito I. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucl Acid Res 1995; 23: 3816-3821.
48. Sakamoto T, Kawazoe Y, Shen JS, Takeda Y, Arakawa Y, Ogawa J et al. Adenoviral gene transfer of GDNF, BDNF and TGFβ2, but not CNTF, cardiotrophin-1 or IGF1, protects injured adult motoneurons after facial nerve avulsion. J Neurosci Res 2003; 72: 54-64.